Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
